GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » Investments And Advances

Eisai Co (TSE:4523) Investments And Advances : 円0 Mil (As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Eisai Co Investments And Advances?

Eisai Co's Investments And Advances for the quarter that ended in Dec. 2023 was 円0 Mil.


Eisai Co Investments And Advances Historical Data

The historical data trend for Eisai Co's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Investments And Advances Chart

Eisai Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eisai Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Eisai Co Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Eisai Co (TSE:4523) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines